ES2183805T3 - Procedimiento de preparacion de un medicamento trombolitico. - Google Patents

Procedimiento de preparacion de un medicamento trombolitico.

Info

Publication number
ES2183805T3
ES2183805T3 ES92890147T ES92890147T ES2183805T3 ES 2183805 T3 ES2183805 T3 ES 2183805T3 ES 92890147 T ES92890147 T ES 92890147T ES 92890147 T ES92890147 T ES 92890147T ES 2183805 T3 ES2183805 T3 ES 2183805T3
Authority
ES
Spain
Prior art keywords
thrombolitic
procedure
preparation
medicinal product
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92890147T
Other languages
English (en)
Inventor
Johann Dr Eibl
Yendra Dr Linnau
Anton Philapitsch
Hans Peter Doz Dr Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3509618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2183805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2183805T3 publication Critical patent/ES2183805T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION CONCIERNE A UN MEDICAMENTO DE ADMINISTRACION PARENTERAL CON EFECTO TROMBOLITICO QUE CONTIENE PROTEINA C ACTIVADA, LA CUAL ESTA LIBRE DE TROMBOACTIVIDAD Y NO CONTIENE ANTICUERPOS CONTRA LA PROTEINA C O PROTEINA C ACTIVADA; ESTE MEDICAMENTO ESTA CARACTERIZADO PORQUE ESTA LIBRE DE AMILIODE SERICO P Y AGENTES INFECCIOSOS. EL MEDICAMENTO DE LA INVENCION ES APROPIADO PARA DISOLVER TROMBOS VENOSOS Y NO POSEE EFECTOS SECUNDARIOS COMO REDUCCION DEL FIBRINOGENO O HEMORRAGIAS.
ES92890147T 1991-06-20 1992-06-16 Procedimiento de preparacion de un medicamento trombolitico. Expired - Lifetime ES2183805T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0123991A AT402262B (de) 1991-06-20 1991-06-20 Arzneimittel enthaltend aktiviertes protein c

Publications (1)

Publication Number Publication Date
ES2183805T3 true ES2183805T3 (es) 2003-04-01

Family

ID=3509618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92890147T Expired - Lifetime ES2183805T3 (es) 1991-06-20 1992-06-16 Procedimiento de preparacion de un medicamento trombolitico.

Country Status (9)

Country Link
US (2) US5580962A (es)
EP (1) EP0519903B1 (es)
JP (1) JP3032085B2 (es)
AT (2) AT402262B (es)
AU (1) AU657758B2 (es)
CA (1) CA2071651C (es)
DE (1) DE59209967D1 (es)
DK (1) DK0519903T3 (es)
ES (1) ES2183805T3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
ES2179129T3 (es) * 1995-03-21 2003-01-16 Baxter Ag Agente para la aplicacion subcutanea de la proteina c.
US5863896A (en) * 1995-11-09 1999-01-26 Immuno Ag Evaluation of substances for altering and for increasing APC response
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
ZA983496B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Methods for processing activated protein C.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6264596B1 (en) 1997-11-03 2001-07-24 Meadox Medicals, Inc. In-situ radioactive medical device
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE235915T1 (de) 1998-11-20 2003-04-15 Lilly Co Eli Behandlung von hämorrhagischem virusfieber mit protein c
BR9915572A (pt) 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
US6733451B2 (en) 1999-10-05 2004-05-11 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic probe used with a pharmacological agent
US6551337B1 (en) 1999-10-05 2003-04-22 Omnisonics Medical Technologies, Inc. Ultrasonic medical device operating in a transverse mode
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US6524251B2 (en) 1999-10-05 2003-02-25 Omnisonics Medical Technologies, Inc. Ultrasonic device for tissue ablation and sheath for use therewith
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050061B2 (en) * 1980-10-06 1990-06-20 New York Blood Center, Inc. Method of reducing undesirable activities of biological and pharmaceutical products
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3544663A1 (de) * 1985-12-13 1987-06-19 Schering Ag Thrombosebehandlung mit fibrinolytika und prostacyclinen
DE3882411T2 (de) * 1987-04-17 1993-12-16 Teijin Ltd Verfahren zur Trennung von aktiviertem menschlichem Protein C.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
FR2658517B2 (fr) * 1989-04-12 1992-06-19 Fondation Nale Transfusion San Preparation de la proteine c activee et solution de proteine c activee ainsi obtenue.
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives

Also Published As

Publication number Publication date
EP0519903A1 (de) 1992-12-23
CA2071651A1 (en) 1992-12-21
AU657758B2 (en) 1995-03-23
DK0519903T3 (da) 2003-01-27
US5478558A (en) 1995-12-26
JPH05170666A (ja) 1993-07-09
AU1830392A (en) 1992-12-24
EP0519903B1 (de) 2002-09-25
DE59209967D1 (de) 2002-10-31
US5580962A (en) 1996-12-03
AT402262B (de) 1997-03-25
ATE224728T1 (de) 2002-10-15
JP3032085B2 (ja) 2000-04-10
ATA123991A (de) 1996-08-15
CA2071651C (en) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE224728T1 (de) Arzneimittel enthaltend aktiviertes protein c
FI885331A0 (fi) Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli.
Giles et al. A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo
GB8824591D0 (en) Fractionation process
FI963802A0 (fi) Trombolyyttisesti aktiivisten proteiinien ja antikoagulanttien yhdistelmiä ja niiden käyttöjä
DE69331758D1 (de) Fibrinogen-bildungsprotein
DE3850531D1 (de) Gewebe-Plasminogenaktivator.
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69129331D1 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
ATE215967T1 (de) Aus harn isolierte antikoagulierende verbindung
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
DE68908913D1 (de) Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.
NO924453D0 (no) Fremgangsmaate for fremstilling av et pasteurisert trombinkonsentrat
DE3751218D1 (de) Verfahren und therapeutische Zubereitungen für die Behandlung von Gerinnungsstörungen.
Hoffman et al. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
ATE78292T1 (de) Plasminogen-aktivator und thrombolytische zusammensetzung.
DK213589D0 (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
NO951219D0 (no) Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav
FI961505A7 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset pep tidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät fa rmaseuttiset koostumukset
ES2107460T3 (es) Tratamiento de la trombosis.
DE69003342D1 (de) Pharmazeutische Zusammensetzungen.
RU93039306A (ru) Антипротеиназный препарат
FR2623628B1 (fr) Serum etalon, de nature humaine, reconstitue a partir des fractions rejetees (non utilisees en therapeutique), du fractionnement du plasma humain, du sang humain, du sang placentaire ou retroplacentaire